Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
268
resultados
Última actualización
11/09/2026 [06:54:00]
Resultados 100 a 125 de 268
Resumen de: US20260256146A1
0000 A cerium oxide nanoparticle is produced by adding an oxidant to a solution comprising a boron compound represented by formula (I) and a cerium (III) ion:
0000
wherein n represents an integer of 0 to 2, R represents any of an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and R′ represents any of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and when a plurality of Rs or of R's are present, the plurality of Rs or of R's are optionally the same or different.
Resumen de: CN115484932A
Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents to alter the expression and function of target genes, such as proteins involved in lipid and cholesterol metabolism, such as PCSK9. Also provided herein are compositions and methods for treating conditions associated with coronary artery disease.
Resumen de: US20260256690A1
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Fibroblast growth factor is to correct structural defects of neural tissue.
Resumen de: AU2026216842A1
The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen. ug u g
Resumen de: US20260256776A1
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
Resumen de: US20260258411A1
0000 The present disclosure is directed to self-cleaving ribozyme constructs designed to target specific organisms and introduce exogenous sequences—both coding and non-coding-into expressed RNAs of the target host cell.
Resumen de: US20260258503A1
According to one embodiment of the present disclosure, a method for fusing lipid nanoparticles is provided. In some embodiments, the method is a method including: causing a fibrous structure to capture a first lipid nanoparticle; causing the fibrous structure to capture a second lipid nanoparticle; and causing the fibrous structure to contract.
Resumen de: US20260256963A1
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.
Resumen de: US20260256940A1
0000 The current invention focuses on ways to deliver various payloads including nucleic acids molecules (such as oligonucleotides), polypeptides (such as proteins), drugs or a combination thereof. As such, the invention relates to, inter alia, a mitochondrion comprising one or more payload(s) attached to the outer membrane of the mitochondrion, wherein the payload(s) is indirectly or directly electrostatically attached to the outer membrane of the mitochondrion. The invention further involves combining mitochondria comprising one or more payload(s) attached to the outer membrane of the mitochondrion with a protective layer that envelopes/encapsules and/or coats the mitochondrion and payload to provide a further delivery platform. This methodology is particularly effective for increasing the uptake and efficiency of the one or more payload(s) for therapeutic purposes.
Resumen de: US20260257986A1
0000 The present invention introduces a novel amino acid-based cationic lipid, represented by the general formula (1), with symbols as defined herein. This lipid is pharmaceutically acceptable, biodegradable, or highly biocompatible, and offers low toxicity, low immunogenicity, and high compatibility. The amino acid or its derivatives used as starting materials are easily accessible, either naturally or through simple synthesis, making the process straightforward, safe, and cost-effective. The lipid structure may include degradable groups between the amino acid residue and lipophilic tail chains. The presence of degradable groups allows lipid nanoparticles (LNPs) to degrade within endosomes, addressing issues of LNP accumulation and endosomal acidification caused by non-degradable lipids in prior art. This facilitates the effective endosomal escape of drug molecules, such as nucleic acids, ensuring their proper cellular function after delivery.
0000
Resumen de: US20260256917A1
To provide a surface-modified nanodiamond that enables selective accumulation of a sufficient amount of boron atoms in a cancer tissue or a cancer cell and has high killing and injuring ability against the cancer cell. The surface-modified nanodiamond of the present disclosure contains a nanodiamond particle, and a boron cluster-containing group and a group capable of recognizing a cancer cell as surface modification groups of the nanodiamond particle.
Resumen de: US20260258002A1
0000 Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticle compositions further including biologically active agents such as mRNA or DNA are useful in the delivery of biologically active agents to mammalian cells or organs.
Resumen de: US20260258177A1
The present invention relates to a process for the synthesis of poly(spermine acrylamide) and/or poly(spermine acrylamide-co-N-alkylacrylamide), the process comprising the following steps: a) reacting a mixture of N-acryloxysuccinimide with N-alkylacrylamide, and b) obtaining poly(N-acryloxysuccinimde) polymers, poly(N-alkylacrylamide) polymers and/or copolymers with varying ratios of N-acryloxysuccinimide and N-alkylacrylamide, and c) treating the obtained polymers and/or copolymers of step b) with at least 0.1 equivalent of tri-boc spermine per N-acryloxysuccinimide-repeating unit and obtaining poly(spermine acrylamide) and/or poly(spermine acrylamide-co-N-alkylacrylamide) polymers.
Resumen de: US20260256696A1
0000 The present invention provides lipid nanoparticles containing
(A) an ionic lipid represented by the formula (1):
0000
0000 (the symbols in the formula (1) are as defined in the DESCRIPTION),
(B) vitamin E and/or a derivative thereof,
(C) phospholipid,
(D) cholesterol, and
(E) PEG lipid.
Resumen de: US20260256705A1
0000 Provided is a lipid formulation capable of forming a lipid-based nanoparticle comprising an ionizable lipid to phospholipid molar ratio of 0.1-1.30 of in association with a nucleic acid payload, and in some embodiments, a stabilizing agent. In embodiments, the nucleic acid payload is a vaccine genetic element.
Resumen de: WO2026179540A1
The present invention belongs to the field of biomedical science, and specifically relates to the use of an iron nanoparticle in the preparation of a product for controlling Babesia. The iron nanoparticle is in the form of a polysaccharide-coated superparamagnetic iron oxide injection or other formulated products containing the main active ingredient thereof. The iron nanoparticle is used for administration to a subject in the presence of a magnetic field. It has been demonstrated by experiments of the present invention that the iron nanoparticle has a good control effect on Babesia with a weak reproductive capacity under the action of an external magnetic field.
Resumen de: US20260256707A1
Disclosed herein are aspects of a compound according to Formula IAlso disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.
Resumen de: WO2025049928A1
A gene editing system comprising (a) a fusion polypeptide comprising a CRISPR nuclease and a reverse transcriptase, or a nucleic acid encoding the fusion polypeptide, and (b) an RNA molecule comprising a guide RNA and a reverse transcription donor RNA, or a nucleic acid encoding the RNA molecule. Also provided herein are methods of using the gene editing system for modifying target genes of interest.
Resumen de: WO2025160108A1
This invention describes therapeutic compositions, uses and methods using deciparticles for cancer drug delivery. Deciparticle compositions of this invention can be composed of one or more taxane drug compounds complexed with amphiphilic molecules. The amphiphilic molecules may comprise a polyethylene glycol hydrophilic oligomer and a fatty acid alkanoyl hydrophobic core.
Resumen de: WO2025152910A1
Disclosed is an engineered exosome, comprising (a) an EGF polypeptide, fused to a first anchoring polypeptide, (b) a NGF polypeptide, fused to a second anchoring polypeptide, and (c) a PDGF-BB polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the EGF polypeptide, the NGF polypeptide and the PDGF-BB polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome for wound healing.
Resumen de: US20260256709A1
0000 Described herein are methods, systems and compositions for the production and use of a class of highly branched, nanostructured particles, generally referred to herein as dendritic particles (DPs), synthesized from biodegradable materials that are specifically adapted for drug release in vivo.
Resumen de: WO2026179183A1
A hafnium-based complex protein nanoparticle for radiotherapy sensitization, a preparation method therefor and the use thereof. Hafnium ions in solution are used, which enter a protein cavity and then form a complex (precipitate) with hexametaphosphate ligand ions, i.e., biomineralization occurs (with the preparation being completed at room temperature), thereby obtaining a protein-encapsulated hafnium-based complex nanoparticle. When exposed to X-ray radiation, the nanoparticle can enhance the effect of radiotherapy.
Resumen de: US20260258413A1
Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.
Resumen de: US20260258407A1
0000 Compositions and methods for reducing complement activation by introducing one or more alterations into a complement factor B (CFB) polynucleotide in a cell. In particular embodiments, the invention of the disclosure features a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a CFB polynucleotide, where the modification is associated with reduced expression, and/or reduced activity of the CFB polypeptide encoded by the polynucleotide.
Nº publicación: US20260258142A1 03/09/2026
Solicitante:
UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Resumen de: US20260258142A1
0000 The presently disclosed subject matter relates to antibodies and antigen-binding fragments that bind specifically to phosphorylated PDGFRA, and methods of treating cancer expressing MAN2A1-FER which ectopically phosphorylates PDGFRA. MAN2A1-FER can be expressed in liver cancer, prostate cancer, brain cancer, glioblastoma multiforme, breast cancer, lung cancer, non-small cell lung cancer, colon cancer, and renal cell carcinoma.
BOPI
Sede Electrónica
